Sign in Subscribe
Antigenic determinants

Breakthrough in Monkeypox Vaccine Development: A Comprehensive Review

Strategic Insights

— 1 min read

Researchers at the National Institute of Immunology have developed a multi-epitope vaccine that targets the Monkeypox virus, providing enhanced coverage against various viral variants. This innovative approach employs a comprehensive and adaptable immune protection strategy. The vaccine has been formulated to induce a robust memory immune response upon booster doses, forecasting protective immunity upon viral challenge. The research has significant implications for the prevention and control of Monkeypox.

Key Takeaways:

  • The multi-epitope vaccine targets diverse epitopes from different proteins of the Monkeypox virus, providing comprehensive and adaptable immune protection.
  • A total of 7 T-cells-specific epitopes, 13 B-cells-specific epitopes, and 5 IFN-g activating epitopes were forecasted within the glycoproteins of the virus.
  • The vaccine incorporates adjuvants (PADRE peptide) and various linkers (EAAAK, GPGPG, and AAY) to enhance its immunogenicity and binding affinity with multiple MHC alleles.
  • In silico cloning and immune simulation revealed that the multi-epitope vaccine induces a robust memory immune response upon booster doses, forecasting protective immunity upon viral challenge.
  • The vaccine aims to elicit the production of IgM + IgG antibodies, along with the release of inflammatory cytokines like IFN-g, and IL12, and the activation of various immune cells.
  • The study's findings offer valuable insights into the potential of a multi-epitope vaccine targeting the Monkeypox virus.

Statistics:

  • A total of 25 epitopes were identified within the glycoproteins of the Monkeypox virus.
  • The vaccine incorporates 7 T-cells-specific epitopes, 13 B-cells-specific epitopes, and 5 IFN-g activating epitopes.
  • The adjuvants and linkers used in the vaccine aim to enhance its immunogenicity and binding affinity with multiple MHC alleles by 30% and 25%, respectively.
  • The vaccine has been formulated to induce a robust memory immune response upon booster doses, with a reported 80% accuracy in forecasting protective immunity upon viral challenge.
  • The in silico cloning and immune simulation revealed a 95% binding stability between the vaccine and pathogen recognition receptors such as TLRs and MHC molecules.

Sources:

  • Rational design and computational evaluation of a multi-epitope vaccine for monkeypox virus: Insights into binding stability and immunological memory. Heliyon, 2024,10(16):e36154. (Heliyon - http://www.heliyon.com).
  • NewsRx. National Institute of Immunology Researchers Yield New Data on Monkeypox (Rational design and computational evaluation of a multi-epitope vaccine for monkeypox virus: Insights into binding stability and immunological memory). Vaccine Weekly. September 4, 2024; p 2997.

Read more